The article reports on a collaboration formed by Cephalon with Mesoblast for the development and commercialization of adult mesenchymal precursor cell therapies. Under the collaboration, Cephalon will oversee phase 2b and 3 trials if the mesenchymal stem cell (MSC) therapy will translate to larger trials, and will retain global commercialization rights. The clinical significance of the MSC therapy is also cited.